JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
At the 44th Annual J.P. Morgan Healthcare Conference, Atea Pharmaceuticals outlined its strategy for hepatitis C virus (HCV), showcasing its…
Infectious Diseases
-
-
JPM26: Enanta outlines strategy to lead in RSV therapeutics
At the 44th Annual J.P. Morgan Healthcare Conference, Enanta Pharmaceuticals discussed its respiratory syncytial virus (RSV) portfolio and the need…
-
JPM26: HIV pipeline dosing optionality gives Gilead advantage
Gilead’s range of treatments and prevention for human immunodeficiency virus (HIV), both on the market and in the pipeline, provides…
-
GSK to file for approval of hep B drug on positive Phase III data
GSK’s triple-action investigational antisense oligonucleotide (ASO) candidate has demonstrated a clinically and statistically significant functional cure in chronic hepatitis B…
-
Sanofi buys hep B vaccine maker for $2.2bn
Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's…
-
UK approves Gilead’s twice-yearly HIV PrEP drug
Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering…
-
CDC ends universal newborn hepatitis B vaccine recommendations
The US Centers for Disease and Prevention (CDC) no longer recommends that all US newborns receive the hepatitis B vaccine,…
-
First gonorrhoea antibiotics in decades herald new era of treatment
Approvals in the US for a pair of new oral antibiotics for gonorrhoea represent a significant improvement in efforts to…
-
Mirum to buy Bluejay for up to $820m in rare liver disease push
Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics in a deal worth up to $820m, adding a Phase III liver…
-
“Sharp” funding cuts disrupt PrEP access to millions of HIV patients
The World Health Organization (WHO) has called for access expansion to newly approved human immunodeficiency virus (HIV) medication amid “sharp…
